Merja Santaniemi1, Y Antero Kesäniemi, Olavi Ukkola. 1. Department of Internal Medicine and Biocenter Oulu, University of Oulu, PO Box 5000, 90014 Oulu, Finland. merja.santaniemi@oulu.fi
Abstract
OBJECTIVE: Adiponectin is an adipocytokine known to be decreased in obesity. It functions in glucose and fatty acid metabolism and also has an anti-inflammatory role in microvasculature. We wanted to investigate the role of adiponectin as a biomarker of metabolic syndrome (MS) and see how the plasma adiponectin levels relate to new criteria of MS proposed by the International Diabetes Federation. METHODS: Plasma adiponectin concentrations were measured from total of 1041 Finnish subjects with an ELISA - a novel method planned in our laboratory. RESULTS: In both the sexes, the plasma adiponectin levels were lower in subjects with MS when compared with subjects with no diagnosis of MS (P< 0.001). Plasma adiponectin levels did not differ between subjects with National Cholesterol Education Program (ATPIII) and International Diabetes Federation-defined MS. Lower adiponectin levels were associated with different components of the MS and there was a trend towards decreasing adiponectin levels with an increasing number of components of MS in both the sexes. Subjects in the lowest adiponectin quartile had a significantly higher probability of having MS (P< 0.001), 4.4-fold in males and 7.5-fold in females, when compared with the corresponding individuals in the highest quartile. The probability increased in every lowering quartile of adiponectin level and was independent of body mass index. CONCLUSION: We conclude that adiponectin levels correlate with most of the components of the MS and the metabolic cluster per se.
OBJECTIVE:Adiponectin is an adipocytokine known to be decreased in obesity. It functions in glucose and fatty acid metabolism and also has an anti-inflammatory role in microvasculature. We wanted to investigate the role of adiponectin as a biomarker of metabolic syndrome (MS) and see how the plasma adiponectin levels relate to new criteria of MS proposed by the International Diabetes Federation. METHODS: Plasma adiponectin concentrations were measured from total of 1041 Finnish subjects with an ELISA - a novel method planned in our laboratory. RESULTS: In both the sexes, the plasma adiponectin levels were lower in subjects with MS when compared with subjects with no diagnosis of MS (P< 0.001). Plasma adiponectin levels did not differ between subjects with National Cholesterol Education Program (ATPIII) and International Diabetes Federation-defined MS. Lower adiponectin levels were associated with different components of the MS and there was a trend towards decreasing adiponectin levels with an increasing number of components of MS in both the sexes. Subjects in the lowest adiponectin quartile had a significantly higher probability of having MS (P< 0.001), 4.4-fold in males and 7.5-fold in females, when compared with the corresponding individuals in the highest quartile. The probability increased in every lowering quartile of adiponectin level and was independent of body mass index. CONCLUSION: We conclude that adiponectin levels correlate with most of the components of the MS and the metabolic cluster per se.
Authors: Laura Kananen; Mikko Hurme; Alexander Bürkle; Maria Moreno-Villanueva; Jürgen Bernhardt; Florence Debacq-Chainiaux; Beatrix Grubeck-Loebenstein; Marco Malavolta; Andrea Basso; Francesco Piacenza; Sebastiano Collino; Efstathios S Gonos; Ewa Sikora; Daniela Gradinaru; Eugene H J M Jansen; Martijn E T Dollé; Michel Salmon; Wolfgang Stuetz; Daniela Weber; Tilman Grune; Nicolle Breusing; Andreas Simm; Miriam Capri; Claudio Franceschi; Eline Slagboom; Duncan Talbot; Claude Libert; Jani Raitanen; Seppo Koskinen; Tommi Härkänen; Sari Stenholm; Mika Ala-Korpela; Terho Lehtimäki; Olli T Raitakari; Olavi Ukkola; Mika Kähönen; Marja Jylhä; Juulia Jylhävä Journal: Geroscience Date: 2022-07-21 Impact factor: 7.581
Authors: Olli-Juhani Galla; Antti Ylitalo; Antti Kiviniemi; Heikki Huikuri; Y Antero Kesäniemi; Olavi Ukkola Journal: Ann Med Date: 2020-03-22 Impact factor: 4.709
Authors: Xiyun Deng; Yanna Cao; Maria P Huby; Chaojun Duan; Lisa Baer; Zhanglong Peng; Rosemary A Kozar; Marie-Francoise Doursout; John B Holcomb; Charles E Wade; Tien C Ko Journal: Shock Date: 2016-01 Impact factor: 3.454
Authors: Glenn C Rowe; Cheol Soo Choi; Lynn Neff; William C Horne; Gerald I Shulman; Roland Baron Journal: Endocrinology Date: 2008-09-04 Impact factor: 4.736